NCT03617328 2024-02-06
Mel-65
University of Virginia
Phase 1/2 Completed
Clinical Trials
13 trialsNCT02425306 2023-10-30
Mel63; CHAMP
University of Virginia
Phase 1/2 Terminated
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00145158 2022-10-10
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Terminated
NCT00365937 2019-03-06
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1/2 Terminated
NCT01748747 2018-10-09
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT01585350 2016-08-12
MEL58
University of Virginia
Phase 1 Completed
NCT00003224 2014-11-20
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Virginia
Phase 1 Completed
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00085189 2014-05-22
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
University of Southern California
Phase 2 Completed
NCT00184067 2014-05-21
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
University of Southern California
Phase 2 Terminated
NCT00112216 2013-04-24
Immunotherapy of Melanoma Patients
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT00912574 2009-06-03
MEL38
University of Virginia
Phase NA Completed